Navigation Links
Europe to tackle brain disorder research by linking industry, academia
Date:11/27/2007

Attempts to cure brain-related disorders have proved less successful than therapies for other major conditions such as heart cancer, even though just as many people suffer from them. About 600 million worldwide each year are afflicted by depression alone, more than any other condition except heart disease, and yet of those given existing drugs, only half recover.

Furthermore progress treating depression as well as other major brain disorders has stalled. This stark fact lies behind an ambitious European proposal to revive the field. The proposal, to be presented at EuroBioForum, in Lisbon in December 2007, aims to develop a ground breaking multi-disciplinary research project which would propel Europe to the head of global research into the crucial role of neurotransmitters in brain disorders. Bringing together the relevant specialisms in chemistry, radio-chemistry, in vivo modelling, and above all PET and SPECT scanning, the project would exploit recent advances both in PET (Positron Emission Tomography), and SPECT (Single Photon Emission Computer Tomography), enabling metabolic activity such as levels of neurotransmitters to be determined with greater accuracy in space and quantity.

The objective is to develop new methods to identify the release of neurotransmitters such as noradrenaline, serotonin, acetylcholine, and endorphins, in the brain and so examine their role in major brain disorders. This in turn will enable more effective therapies to be developed than current drugs, which often fail to work, according to the projects leader David Nutt, Professor of Psychopharmacology at the University of Bristol, UK. Professor Nutt is presenting his vision for this groundbreaking project at the EuroBioForum conference, which is organised by the European Science Foundation (ESF) with support from the European Commission.

The programme has great potential for human health given the vast number of people affected, but as Professor Nutt pointed out, the scale of the task is great.

We dont even know for example whether serotonin levels are high or low in depressed people, said Professor Nutt. This is despite the fact that many current anti-depressant drugs, including Prozac, alter the uptake of serotonin by key receptors in the brain. Professor Nutts observation shows that there is a lack of knowledge over how existing drugs work, and until greater understanding is reached, it will be very difficult to make further progress.

Until now researchers have been deterred by the sheer extent of the problem in unravelling the complex links between multiple neurotransmitters and a range of conditions. This, said Professor Nutt, is big science on the same level as the Human Genome Project, or splitting the atom. It requires a huge harmonised effort, combining the forces of academia and the pharmaceutical industry. Until now neurological research has tended to be fragmented, with industry more concerned with improving existing therapies and determining correct combinations of drugs and dosage levels. Meanwhile academia has tended to plough too many small furrows, without tackling the big picture.

The EuroBioForum conference will provide the platform for researchers to unite behind a common larger goal. As Professor Nutt commented, the conference offers a unique opportunity for the academic community, research funding organisations, government, industry and policy making organisations to share ideas and contribute to key policy and funding decisions. He added, Im extremely pleased to have been invited to such an important event and delighted that for the first time a brain research programme has been shortlisted under this initiative.


'/>"/>

Contact: Dr. Fiona Kernan
fkernan@esf.org
33-388-762-180
European Science Foundation
Source:Eurekalert

Related medicine news :

1. Eligard(R) six-month formulation successfully completes European approval procedure
2. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
3. Medical Services International Inc. Completes Testing for European Union (EU) Application
4. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
5. Europe-wide Researchers Night
6. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
7. Launch of second European Cancer Research Funding survey
8. Cancer control in Europe works; now it is time to extend it to poorer countries
9. Political decisions harming cancer treatment in Europe
10. European directive will halt use of MRI scans; cancer diagnosis and treatment will suffer
11. Stille and Enova Form Strategic Partnership to Introduce Worlds Brightest LED Cordless Surgical Headlights Into Europe and Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2017)... ... 22, 2017 , ... "Photo Cloud allows FCPX users to add favorited photos ... complete ease," said Christina Austin - CEO of Pixel Film Studios. , To ... timeline. Presets include scenes with one, three, four or five focus points. There ...
(Date:1/21/2017)... ... January 21, 2017 , ... Caronlab Australia, an Australian company ... ECRM Trade Show in Hilton Head, SC, where it benefited from outstanding meetings with ... of its beauty and wellness products. At this trade show, the company had the ...
(Date:1/21/2017)... ... ... "ProDOF is the perfect set of tools for video editors that want to create the ... Austin - CEO of Pixel Film Studios. , Video editors using ProDOF can add ... DSLR racking focus from one area into the next. ProDOF comes with 0.5 second, ...
(Date:1/21/2017)... ... January 21, 2017 , ... Phytocéane invites you to take ... rest of the world with ZANZIBAR SHOWER GEL. Inspired by the beauty of Zanzibar, ... Coconut Oil and moisturizing vegetal coral to create this gentle, crystal-clear shower gel to ...
(Date:1/21/2017)... ... January 21, 2017 , ... Northern California ... has recently joined their multi-specialty medical group. The dermatology practice provides general dermatologic ... “We’re excited to add this excellent dermatology practice to our group’s medical services,” ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... 20, 2017 Avillion LLP, a co-developer and ... Mark Weinberg , MD MBA as Chief Medical Officer. Dr Weinberg ... USA . ... Dr Weinberg has spent more than 17 years as a pharmaceutical ... to micro-cap biotech. Over the course of his career, he has ...
(Date:1/19/2017)... , Jan. 19, 2017 The U.S. Food and ... Chronic Idiopathic Constipation (CIC) in adult patients. ... gastrointestinal disorders," said Julie Beitz , M.D., director of ... for Drug Evaluation and Research. "With the availability of new ... treatment for their condition." ...
(Date:1/19/2017)... , Jan. 19, 2017  Stealth BioTherapeutics Inc. ( ... treat mitochondrial dysfunction, today announced new additions to its ... as Chief Medical Officer, and Daniel Geffken ... that Jim Carr , Pharm.D. has been promoted ... are pleased to welcome Doug and Daniel to our ...
Breaking Medicine Technology: